Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
Pulse Biosciences, Inc. developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a podium presentation and a product theatre presentation at the Annual North American Society for Interventional Thyroidology 2026 meeting, being held March 6-7 in Portland, Oregon.
“We are pleased to share promising long-term follow up data for patients treated in the nPulse Vybrance feasibility study, with patients now having been followed for up to 22 months,” said Paul LaViolette, Co-Chairman of Pulse Biosciences’ Board of Directors. “We would like to thank Prof. Stefano Spieza, the team at Ospedale del Mare in Naples, Italy, and our nPulse Vybrance investigators for continuing to advance the treatment of benign thyroid nodules with nsPFA technology. We look forward to engaging with the entire clinical community at this important meeting. Much work and analysis remains to be managed.”
Key nPulse Technology Scientific Programming
Friday, March 6th
- 4:40pm, Prof. Stefano Spiezia – Clinical Science Session
- Title: Interim Report: Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation – Durability of Volume and Symptom Reduction
- Review of the long-term follow up at 15-22 months for patients treated in the initial feasibility study of nPulse Vybrance technology used for the ablation of benign, symptomatic thyroid nodules
Saturday, March 7th, Product Theatre Presentation
- 7:00-7:45am, Ralph Tufano, MD, Prof. Stefano Spiezia, Emad Kandil, MD, Kepal Patel, MD
- Title: nPulse Technology – the Potential of Nonthermal Ablation with nsPFA Energy is a work in process
- Roundtable presentation by top nPulse users on the technology, mechanism of action, results, and case studies of the use of nPulse Vybrance technology for benign, symptomatic thyroid nodules
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Source link: https://www.businesswire.com/
